Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts
Challenges of Implementing and Validating CTC Assays in Oncology Clinical Trials
Iman Jilani, Pfizer, speaking at Exosomes and Circulating Biomarkers Summit 2013.
Date Posted: Sunday, March 30, 2014
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Pfizer Enters into Agreement with GlaxoSmithKline
Agreement with GSK to acquire Nimenrix and Mencevax vaccines.
Thursday, June 25, 2015
Pfizer Acquires Minority Interest in AM-Pharma
Option to acquire company may be exercised based on Phase II trial results for recombinant human Alkaline Phosphatase.
Tuesday, May 12, 2015
Merck and Pfizer Finalize Agreement to Co-Promote XALKORI®
Co-promotion of XALKORI allows the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer to establish a combined oncology sales organization in key markets for the program.
Thursday, April 09, 2015
Pfizer to Acquire Hospira for $17B
Companies have into a definitive merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion.
Thursday, February 05, 2015
Pfizer Acquires Redvax
Acquisition provides Pfizer with a preclinical CMV vaccine candidate.
Thursday, January 08, 2015
Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform
Signs collaboration with Spark Therapeutics to advance phase 1/2 Adeno-associated virus (AAV) vector program in hemophilia B.
Friday, December 12, 2014
Pfizer, Merck to Evaluate Novel Anti-Cancer Combination Regimen
This multi-center, open-label clinical study will be conducted by Pfizer and is expected to begin in 2015.
Wednesday, August 27, 2014
Pfizer to Acquire InnoPharma
Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.
Wednesday, July 16, 2014
Pfizer Confirms Interest in AstraZeneca
Pfizer submitted a preliminary, non-binding indication of interest to the board of directors of AZ in January 2014 regarding a possible merger transaction.
Monday, April 28, 2014
Pfizer Announces Plan for Split-Off of Zoetis
The offer better positions Pfizer to focus on its core business as an innovative biopharmaceutical company.
Thursday, May 23, 2013
Pfizer Presents Phase 3 Safety And Immunogenicity Data On HIV Drug
Pfizer Inc. presented the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13® in adults infected with HIV.
Tuesday, March 05, 2013
Pfizer Announces Resolutions with DOJ and SEC Related to Certain International Operations
U.S. agencies praise Company’s cooperation and compliance program.
Thursday, August 09, 2012
Pfizer Announces Positive Results From Phase 3 Cancer Study
Study PROFILE 1007 evaluates XALKORI® (crizotinib) in previously treated patients with ALK-positive advanced non-small cell lung cancer.
Wednesday, June 27, 2012
Pfizer Maneuvers to Protect Lipitor from Generics
Lipitor is so valuable that Pfizer is practically paying people to keep taking its blockbuster cholesterol medicine after generic competition hit the U.S. market last week.
Tuesday, December 06, 2011
Pfizer to Acquire Icagen
Pfizer Inc. and Icagen, Inc. announce that they have entered into a definitive merger agreement.
Thursday, August 04, 2011
Scientific News
Personalized Screening for Ovarian Cancer
With 60% of women diagnosed with ovarian cancer dying within five years of diagnosis there has been considerable efforts to try to detect the disease at an earlier stage.
Regenerative Medicine Biologists Discover a Cellular Structure that Explains Fate of Stem Cells
The findings are presented in the journal Nature.
Boys More Likely to Have Antipsychotics Prescribed, Regardless of Age
NIH-funded study is the first look at antipsychotic prescriptions patterns in the U.S.
Engineering Yeast that Speaks
Scientists at the University of Washington say they have engineered yeast cells that can "talk" to one another, using the plant hormone auxin.
$1.35 Million Grant to Better Predict Flu Outbreaks
An international research team will receive $1.35 million from the Human Frontier Science Program Organization to better understand how the influenza virus passes from birds to humans.
Outsmarting HIV With Vaccine Antigens Made to Order
AIDS vaccine researchers may be one step closer to outwitting HIV, thanks to designer antibodies and antigens made to order at Duke University.
New Tracking Method Yields Insights into Mitochondrial Dynamics
Scientists from the University of Pennsylvania have devised a powerful new technique that enables the tracking of every mitochondrion as it moves within a cell.
More Accurate Prediction on Prognosis in Multiple Myeloma (Bone Marrow Cancer)
Test of Dutch-based SkylineDx gives patients better insight in their chances and enables clinicians to adjust their treatment.
NuGEN Scientists Screen 400+ Genes for Fusion Events in Single Assay
Breakthrough proves efficacy of new sample preparation method that could accelerate cancer research and development of treatments and diagnostic tests.
Team Identifies Gene Responsible for Some Cases of Male Infertility
In the most severe form of male infertility, men do not make any measurable levels of sperm. This condition, called azoospermia, affects approximately 1 percent of the male population and is responsible for about a sixth of cases of male infertility.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters